Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Preferred Stock Liabilities (2024)

Maze Therapeutics' Preferred Stock Liabilities history spans 1 years, with the latest figure at $508.1 million for Q4 2024.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $508.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $508.1 million, a N/A change, with the full-year FY2024 number at $508.1 million, changed N/A from a year prior.
  • Preferred Stock Liabilities hit $508.1 million in Q4 2024 for Maze Therapeutics, up from $383.9 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for MAZE hit a ceiling of $508.1 million in Q4 2024 and a floor of $383.9 million in Q1 2024.